Articles
China Cancer Drugs Market is expected to be US$ 30 Billion by the year 2024
by Renub Research Renub Research is a Market Research and ConsultingIn China, cancer is a
major public health concern. Several factors are responsible for the increasing
prevalence of cancer in China such as extensive use of tobacco, unhealthy
lifestyle and rising geriatric population. Almost one-third of the world’s lung
cancer and nearly half of the liver, stomach and esophageal cases of cancer
occur in China. China Cancer Drugs Market is expected to be US$ 30 Billion by the year 2024.
Cancer drugs act at
various levels – cancer cells, extracellular matrix, endothelium, host cells or
immune system. The cancerous cell can be targeted at the DNA, RNA or protein level. Most available chemotherapy drugs interact with
tumor DNA while targeted drugs (monoclonal antibodies) and small molecules
directed against proteins. With increasing incidence of cancer cases in China,
rising per capita income in the region, growing awareness regarding cancer
coupled with improving healthcare infrastructure and reimbursement on cancer
drugs, it is believed that China Cancer Drugs Market will certainly touch new
leap in the forthcoming years.
The decision of using a
cancer drug depends on several factors, including the type of cancer and the
location of the cancer and its stage. Generally cancer drugs are administered
intravenously; however, some cancer medicines can also be taken orally and
others can be administered intramuscularly or intrathecally (within the spinal
cord). The treatment of cancer is very intricate, the cancer drugs used to
treat cancer cell, sometimes target normal cells, though cells that have undergone
genetic changes and are dividing at a fast and uncontrolled rate. Apparently,
there are certain anticancer drugs which can differentiate between healthy
cells and the cancer cells.
With the advancement in
medicinal technology, in the early 21st century, the identification of
molecular features unique to cancer cells stimulated the evolution of targeted
cancer therapies, which possess a pretty high degree of specificity for cancer
cells. Today, across the globe, targeted therapy for cancer treatment is
gaining popularity because targeted therapy are designed to block the growth
and spread of cancer by interfering with a specific biochemical pathway central
to the development, growth, and spread of that particular cancer unlike
chemotherapy that act on all rapidly dividing normal and cancerous cells.
Click here for: Drugs & Pharmaceuticals Research Reports
Chinese
biopharmaceuticals industry is witnessing a rapid transformation as the
government focuses on an innovation-driven economic by 2020. In the last two decades, China has invested a
total of 18% of the world’s
spending on Research and Development (R&D) across all sectors. Healthcare sector has a specific precedence,
as the Chinese government facing dual challenges of improving the health of the
population and maintaining the growth of the biopharmaceutical industry.
Recently, the Chinese government has stepped up its efforts in reducing the
cost of cancer drugs and has eliminated import tariffs on almost all cancer
drugs, so that the Chinese patients need not have to give up their treatment.
These recent developments will certainly drive China Cancer Drugs Market in
near future.
China Anti Cancer Drugs Market Summary
- On the basis of drugs type Cytotoxic Drugs controls the Anti
Cancer Drugs Market in China. The report is further segmented into
Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, TCM and Others.
Cytotoxic Drugs is further divided into Antimetabolites, Plant Alkaloids
and Alkylating Agents.
- Based on Cancer types, Lung cancer drives the China Anti
Cancer Drugs Market. The other cancer markets studied in the report are as
follows: Lung, Stomach, Breast, Esophageal, Liver & Others.
- On the basis of Therapy type, China Anti Cancer Drugs Market
is divided into following segments Chemotherapy, Targeted Therapy,
Hormonal Therapy and Others.
- Companies studied in the report are as follows: Merck, Celegene, Eli Lilly, Roche, Sino & BioPharma
Sponsor Ads
About Renub Research 
Renub Research is a Market Research and Consulting
7 connections, 0 recommendations, 22 honor points.Joined APSense since, January 12th, 2019, From Roswell, United States.
Created on Feb 8th 2019 23:53. Viewed 327 times.
